HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population.

AbstractBACKGROUND:
CYP1A1, CYP2A6 and CHRNA5 are biologically plausible genes as risk factors for lung cancer but no studies have been reported in the Bangladeshi population.
METHODS:
We conducted this study to determine the prevalence and role of CYP1A1, CYP2A6 and CHRNA5 polymorphisms together with tobacco smoking in the development of lung cancer in Bangladesh. A case-control study was carried out on 106 lung cancer patients and 116 controls to investigate three allelic variants of the CYP1A1 gene-rs4646903, rs1048943 and rs1799814; 2 variants of CYP2A6 (CYP2A6*1B1, CYP2A6*4) and 1 variant of CHRNA5 (rs16969968) using Polymerase Chain Reaction Restriction Fragment Length Polymorphism.
RESULTS:
Lung cancer risk was estimated as odds ratio (OR) and 95% confidence interval (CI) using unconditional logistic regression models adjusting for age, sex and smoking. A significantly elevated lung cancer risk was associated with heterozygous, mutant and combined heterozygous plus mutant variants of CYP1A1 rs4646903. A significant association was also found for heterozygous and heterozygous plus mutant variants of rs1048943 which was in linkage disequilibrium with rs4646903. The risk of lung cancer was decreased significantly in individuals carrying at least one CYP2A6 deletion (CYP2A6*4) allele. No association with lung cancer risk was found for CHRNA5 rs16969968. When stratified by smoking, the effects of CYP1A1 and CYP2A6 polymorphisms on lung cancer susceptibility were found to be significant only in heavy smokers who had smoked 40 pack years or more (54% of all cases) but no associations were seen for lighter smokers. No association was also found with any polymorphism in the non-smokers in this study.
CONCLUSIONS:
Our results indicate that the CYP1A1*2B allele (rs4646903 and rs1048943) is associated with an increased lung cancer risk and CYP2A6*4 is associated with a decreased lung cancer risk in the study population.
AuthorsMohammad Safiqul Islam, Maizbha Uddin Ahmed, Muhammad Shahdaat Bin Sayeed, Abdullah Al Maruf, A G M Mostofa, Syed Md Akram Hussain, Yearul Kabir, Ann K Daly, Abul Hasnat
JournalClinica chimica acta; international journal of clinical chemistry (Clin Chim Acta) Vol. 416 Pg. 11-9 (Feb 01 2013) ISSN: 1873-3492 [Electronic] Netherlands
PMID23178447 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier B.V. All rights reserved.
Chemical References
  • Receptors, Nicotinic
  • Aryl Hydrocarbon Hydroxylases
  • CYP2A6 protein, human
  • Cytochrome P-450 CYP1A1
  • Cytochrome P-450 CYP2A6
Topics
  • Aryl Hydrocarbon Hydroxylases (genetics)
  • Bangladesh (epidemiology)
  • Case-Control Studies
  • Cytochrome P-450 CYP1A1 (genetics)
  • Cytochrome P-450 CYP2A6
  • Genetic Predisposition to Disease
  • Genetic Variation
  • Humans
  • Lung Neoplasms (genetics)
  • Polymerase Chain Reaction
  • Polymorphism, Genetic
  • Receptors, Nicotinic (genetics)
  • Risk Factors
  • Smoking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: